(2M6) Medtronic - Ratings and Ratios
Pacemaker, Insulin, Stent, Pump, Monitor
2M6 EPS (Earnings per Share)
2M6 Revenue
Description: 2M6 Medtronic
Medtronic PLC, listed on XETRA under the ticker symbol 2M6, is a leading player in the Health Care Equipment sub-industry. As an Irish company, it operates globally, providing a range of medical devices and therapies.
The companys financial performance is a key driver of its stock value. Income Tax Expense is a crucial component of its overall profitability. A thorough analysis of this metric can reveal insights into Medtronics tax strategy and its impact on the bottom line.
To evaluate Medtronics performance, key performance indicators (KPIs) such as Return on Equity (RoE) and Price-to-Earnings (P/E) ratio are essential. With a RoE of 9.62%, Medtronic demonstrates a reasonable ability to generate profits from shareholder equity. The P/E ratio of 25.09 suggests that the stock may be slightly overvalued compared to its current earnings, although the forward P/E of 16.50 indicates potential for future earnings growth.
The healthcare equipment industry is driven by factors such as demographic trends, technological advancements, and regulatory changes. The aging global population and the increasing prevalence of chronic diseases drive demand for medical devices and therapies. Medtronics market capitalization of approximately €100.6 billion underscores its significant presence in this market.
Economic drivers such as GDP growth, healthcare expenditure, and innovation in medical technology also impact Medtronics performance. The companys ability to innovate and adapt to changing regulatory environments will be crucial in maintaining its competitive edge. With a beta of 0.820, Medtronics stock price tends to be less volatile than the overall market, potentially making it a more stable investment option for investors seeking exposure to the healthcare sector.
2M6 Stock Overview
| Market Cap in USD | 118,871m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception |
2M6 Stock Ratings
| Growth Rating | -20.9% |
| Fundamental | 66.6% |
| Dividend Rating | 60.4% |
| Return 12m vs S&P 500 | -13.4% |
| Analyst Rating | - |
2M6 Dividends
| Dividend Yield 12m | 3.05% |
| Yield on Cost 5y | 3.06% |
| Annual Growth 5y | 4.12% |
| Payout Consistency | 93.3% |
| Payout Ratio | 72.0% |
2M6 Growth Ratios
| Growth Correlation 3m | 78% |
| Growth Correlation 12m | -37% |
| Growth Correlation 5y | -53.1% |
| CAGR 5y | 0.07% |
| CAGR/Max DD 5y | 0.00 |
| Sharpe Ratio 12m | 0.33 |
| Alpha | -3.79 |
| Beta | 0.158 |
| Volatility | 22.39% |
| Current Volume | 2.1k |
| Average Volume 20d | 1k |
| Stop Loss | 76.2 (-3%) |
| Signal | 0.67 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (4.66b TTM) > 0 and > 6% of Revenue (6% = 2.01b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -0.12pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 32.61% (prev 34.44%; Δ -1.83pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 7.04b > Net Income 4.66b (YES >=105%, WARN >=100%) |
| Net Debt (26.30b) to EBITDA (9.22b) ratio: 2.85 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.29b) change vs 12m ago -2.84% (target <= -2.0% for YES) |
| Gross Margin 65.31% (prev 65.35%; Δ -0.03pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 36.92% (prev 35.97%; Δ 0.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.72 (EBITDA TTM 9.22b / Interest Expense TTM 729.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.03
| (A) 0.12 = (Total Current Assets 23.81b - Total Current Liabilities 12.88b) / Total Assets 91.68b |
| (B) 0.34 = Retained Earnings (Balance) 31.48b / Total Assets 91.68b |
| (C) 0.07 = EBIT TTM 6.36b / Avg Total Assets 90.83b |
| (D) 0.63 = Book Value of Equity 27.19b / Total Liabilities 43.42b |
| Total Rating: 3.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.61
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 3.75% = 1.87 |
| 3. FCF Margin 15.46% = 3.87 |
| 4. Debt/Equity 0.59 = 2.33 |
| 5. Debt/Ebitda 3.09 = -1.89 |
| 6. ROIC - WACC 1.53% = 1.91 |
| 7. RoE 9.62% = 0.80 |
| 8. Rev. Trend 75.81% = 3.79 |
| 9. Rev. CAGR 7.21% = 0.90 |
| 10. EPS Trend 41.81% = 1.05 |
| 11. EPS CAGR 4.83% = 0.48 |
What is the price of 2M6 shares?
Over the past week, the price has changed by -1.33%, over one month by -1.29%, over three months by +9.10% and over the past year by +1.88%.
Is Medtronic a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of 2M6 is around 79.28 EUR . This means that 2M6 is currently overvalued and has a potential downside of 0.88%.
Is 2M6 a buy, sell or hold?
What are the forecasts/targets for the 2M6 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 86 | 9.4% |
2M6 Fundamental Data Overview
Market Cap USD = 118.87b (102.05b EUR * 1.1648 EUR.USD)
CCE Cash And Equivalents = 8.96b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 25.6109
P/E Forward = 16.5289
P/S = 2.984
P/B = 2.4758
P/EG = 2.1623
Beta = 0.817
Revenue TTM = 33.54b USD
EBIT TTM = 6.36b USD
EBITDA TTM = 9.22b USD
Long Term Debt = 25.59b USD (from longTermDebt, last quarter)
Short Term Debt = 2.87b USD (from shortTermDebt, last quarter)
Debt = 28.46b USD (Calculated: Short Term 2.87b + Long Term 25.59b)
Net Debt = 26.30b USD (from netDebt column, last quarter)
Enterprise Value = 138.37b USD (118.87b + Debt 28.46b - CCE 8.96b)
Interest Coverage Ratio = 8.72 (Ebit TTM 6.36b / Interest Expense TTM 729.0m)
FCF Yield = 3.75% (FCF TTM 5.18b / Enterprise Value 138.37b)
FCF Margin = 15.46% (FCF TTM 5.18b / Revenue TTM 33.54b)
Net Margin = 13.90% (Net Income TTM 4.66b / Revenue TTM 33.54b)
Gross Margin = 65.31% ((Revenue TTM 33.54b - Cost of Revenue TTM 11.63b) / Revenue TTM)
Tobins Q-Ratio = 5.09 (Enterprise Value 138.37b / Book Value Of Equity 27.19b)
Interest Expense / Debt = 0.61% (Interest Expense 174.0m / Debt 28.46b)
Taxrate = 16.63% (from yearly Income Tax Expense: 936.0m / 5.63b)
NOPAT = 5.30b (EBIT 6.36b * (1 - 16.63%))
Current Ratio = 1.85 (Total Current Assets 23.81b / Total Current Liabilities 12.88b)
Debt / Equity = 0.59 (Debt 28.46b / last Quarter total Stockholder Equity 48.02b)
Debt / EBITDA = 3.09 (Net Debt 26.30b / EBITDA 9.22b)
Debt / FCF = 5.49 (Debt 28.46b / FCF TTM 5.18b)
Total Stockholder Equity = 48.46b (last 4 quarters mean)
RoA = 5.09% (Net Income 4.66b, Total Assets 91.68b )
RoE = 9.62% (Net Income TTM 4.66b / Total Stockholder Equity 48.46b)
RoCE = 8.58% (Ebit 6.36b / (Equity 48.46b + L.T.Debt 25.59b))
RoIC = 6.95% (NOPAT 5.30b / Invested Capital 76.24b)
WACC = 5.42% (E(118.87b)/V(147.33b) * Re(6.60%)) + (D(28.46b)/V(147.33b) * Rd(0.61%) * (1-Tc(0.17)))
Shares Correlation 5-Years: -100.0 | Cagr: -1.27%
Discount Rate = 6.60% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.20% ; FCFE base≈5.19b ; Y1≈5.16b ; Y5≈5.41b
Fair Price DCF = 74.79 (DCF Value 95.82b / Shares Outstanding 1.28b; 5y FCF grow -1.29% → 3.0% )
Revenue Correlation: 75.81 | Revenue CAGR: 7.21%
Rev Growth-of-Growth: -0.63
EPS Correlation: 41.81 | EPS CAGR: 4.83%
EPS Growth-of-Growth: 17.33